tiprankstipranks
Advertisement
Advertisement
Altimmune Reports Positive Phase 2 Data in AUD
PremiumCompany AnnouncementsAltimmune Reports Positive Phase 2 Data in AUD
5d ago
Altimmune announces RECLAIM trial met primary endpoint
Premium
The Fly
Altimmune announces RECLAIM trial met primary endpoint
5d ago
BWXT, Altimmune, Global Payments, AbbVie, Nike Trending With Analysts
Premium
Weekend Updates
BWXT, Altimmune, Global Payments, AbbVie, Nike Trending With Analysts
1M ago
Altimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide
PremiumThe FlyAltimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide
2M ago
Altimmune price target lowered to $20 from $25 at H.C. Wainwright
Premium
The Fly
Altimmune price target lowered to $20 from $25 at H.C. Wainwright
3M ago
Altimmune price target lowered to $11 from $14 at Citizens
Premium
The Fly
Altimmune price target lowered to $11 from $14 at Citizens
3M ago
Altimmune upgraded to Neutral from Sell at Goldman Sachs
PremiumThe FlyAltimmune upgraded to Neutral from Sell at Goldman Sachs
3M ago
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/23/2026
Premium
Market News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/23/2026
3M ago
Altimmune 64.25M share Spot Secondary priced at $3.00
Premium
The Fly
Altimmune 64.25M share Spot Secondary priced at $3.00
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100